COLLABORATION, LICENSE AND OPTION AGREEMENT By and Between Cue Biopharma, Inc. and LG Chem, Ltd. Dated as of November 6, 2018Collaboration, License and Option Agreement • November 13th, 2018 • Cue Biopharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 13th, 2018 Company Industry JurisdictionTHIS COLLABORATION, LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into as of November 6, 2018 (the “Effective Date”), by and between CUE BIOPHARMA, INC., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG CHEM LTD., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”. Contemporaneously, the Parties are entering into a Stock Purchase Agreement dated the Effective Date for LGC’s purchase of Cue’s publicly traded common stock and an amendment of the Einstein License Agreement (as defined below).